Eli Lilly’s Leading Position in the Weight-Loss Drug Market Remains Solid, Competition Landscape for Oral Drugs Begins to Emerge Sep 19, 2026 Life Science
Johnson & Johnson vs. Kenvue, Which Is Better Suited for a Defensive Dividend Portfolio? Sep 17, 2026 Life Science
From the Financial Crisis to the 2022 Bear Market, How Does Amgen Demonstrate Resilience? Sep 17, 2026 Life Science
Investors Seek Buying Opportunities Before Year-End, These Two Stocks Are Cheaply Valued and Offer Growth Potential Sep 16, 2026 Financial Service, Life Science
Eli Lilly Ramps Up Acquisitions to Diversify Beyond Weight-Loss Drug Dominance Sep 15, 2026 Life Science
Novartis Suffers Three Clinical Setbacks in a Row, So Why Has Eli Lilly Avoided the Vortex? Sep 15, 2026 Life Science
Johnson & Johnson Advances Spin-Off and Sale in Parallel as Orthopedics Business Valued at Nearly $20 Billion Sep 11, 2026 Life Science
Novo Nordisk Scores Pediatric Weight-Loss Trial Win, Unlocking Contrarian Investment Value Sep 11, 2026 Life Science
Broad Coverage or Concentrated Bets? Analyzing the Differences Between Healthcare Funds VHT and XPH Sep 11, 2026 Life Science
From $275 to $461, UnitedHealth Regains Confidence Through a Turnaround Script Sep 9, 2026 Life Science
AbbVie’s Diversification Bet Gradually Shows Results, While Pfizer Seeks a Second Takeoff Through Its GLP-1 and Oncology Pipelines Sep 5, 2026 Life Science
Pfizer Trades Below 10x P/E, But Does That Signal a Value Trap or a Long-Term Opportunity? Sep 4, 2026 Life Science
Eli Lilly Swallows Merida, Expanding Pipeline with Another Strategic Acquisition Sep 3, 2026 Life Science
Gene-Editing Pioneer CRISPR Therapeutics Worth a Bet Before Year-End? Two Catalysts Await Release Sep 3, 2026 Life Science
